Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 31;19(1):2168952.
doi: 10.1080/21645515.2023.2168952. Epub 2023 Mar 14.

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review

Nikolaos Giannelos  1 , Cheryl Ng  2 , Desmond Curran  1
Affiliations
Review

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review

Nikolaos Giannelos et al. Hum Vaccin Immunother. .

Abstract

The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agency websites to identify and collect data from CE studies comparing RZV to zoster vaccine live (ZVL) or to no vaccination. Study characteristics, inputs, and outputs were collected. The overall CE of RZV was assessed. RZV vaccination against HZ is cost-effective in 15 out of 18 studies included in the present review. Varying incremental cost-effectiveness ratios (ICERs) observed may be associated with different assumptions on the duration of protection of RZV, as well as different combinations of structural and disease-related study (model) inputs driving the estimation of ICERs.

Keywords: Herpes zoster; cost-effectiveness; older adults; recombinant zoster vaccine; vaccination.

Plain language summary

What is the context?• Herpes zoster, also known as shingles, may cause painful rashes and skin alterations.• Chronic pain, also referred to as post-herpetic neuralgia, may persist for months or even years after the initial rash.• The disease is caused by reactivation of the varicella zoster virus.• The recombinant zoster vaccine (RZV) and the zoster vaccine live (ZVL) are approved for the prevention of herpes zoster and post-herpetic neuralgia.• We reviewed published evidence from the past 5 years on RZV.What is new?• Out of 18 selected studies, RZV vaccination against herpes zoster and post-herpetic neuralgia is cost-effective in 15.• In the 15 studies establishing RZV cost-effectiveness, RZV is always cost-effective or frequently cost-saving in direct comparisons to ZVL, when applicable.• RZV was found cost-saving in several immune-compromised populations.What is the impact?• The overview of the currently available body of evidence related to cost-effectiveness of RZV may help informing decision makers about the value of vaccination against herpes zoster.

PubMed Disclaimer

Conflict of interest statement

NG, CN and DC are employed by GSK. NG and DC hold shares in GSK. All authors declare no other financial and non-financial relationships and activities.

Figures

Figure 1.
Figure 1.
PRISMA flowchart.
See this image and copyright information in PMC

References

    1. Schmader K. Herpes Zoster. Ann Intern Med. 2018;169(3):1–13. doi: 10.7326/AITC201808070. - DOI - PubMed
    1. van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vacc Immunotherap. 2021;17(6):1714–32. doi: 10.1080/21645515.2020.1847582. - DOI - PMC - PubMed
    1. Coplan PM, Schmader K, Nikas A, Chan ISF, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004;5(6):344–56. doi: 10.1016/j.jpain.2004.06.001. - DOI - PubMed
    1. Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007;7(11):1581–95. doi: 10.1586/14737175.7.11.1581. - DOI - PubMed
    1. Lang P-O, Aspinall R. Vaccination for quality of life: herpes–zoster vaccines. Aging Clin Exp Res. 2021;33(4):1113–22. doi: 10.1007/s40520-019-01374-5. - DOI - PubMed

Publication types